

Department of Radiation Oncology
University of Maryland School of Medicine
Publications 2023 Academic Year (mid-2022 through mid-2023)
(Names in bold represent individuals in the department at the time of publication)

1. Ali A, Waris A, **Khan MA**, Asim M, Khan AU, Khan S, Zeb J. [Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections.](#) *Life Sci.* 2023 Feb 1;314:121332. Epub 2022 Dec 28.
2. Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, **Mohindra P**, Bukhari A, Lutfi F, Sanchez-Petitto G, **Molitoris J**, **Samanta S**, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. [Outcomes of busulfan, fludarabine, and 400 cgy total body irradiation compared with busulfan and fludarabine reduced-intensity conditioning regimens for allogeneic stem cell transplantation in adult patients with hematologic diseases: A single-center experience.](#) *Transplant Proc.* 2023;55(1):214-224.
3. **Allen AJ**, Labella DA, Kowalchuk RO, Waters MR, Kersh CR. [Effect of histology on stereotactic body radiotherapy for non-small cell lung cancer oligometastatic pulmonary lesions.](#) *Transl Lung Cancer Res.* 2023 Jan 31;12(1):66-78. Epub 2023 Jan 16.
4. Amin A, Wu R, **Khan MA**, Cheung MH, Liang Y, Liu C, Zhu G, Yu ZL, Liang C. [An essential Noc3p dimerization cycle mediates ORC double-hexamer formation in replication licensing.](#) *Life Sci Alliance.* 2023 Jan 4;6(3):e202201594.
5. Amin N, Thompson J, Goloubeva O, **Witek M**, Taylor RJ, Wolf JS, Moyer K, Mehra R, Hatten KM. [Human papillomavirus impact on temporal treatment trends in oropharyngeal carcinoma: 2010-2016.](#) *ORL J Otorhinolaryngol Relat Spec.* 2022 Sep 6:1-9. Online ahead of print.
6. Amin NB, Bridgham KM, Brown JP, Moyer KF, Taylor RJ, Wolf JS, Witek ME, **Molitoris JK**, Mehra R, Cullen KJ, Papadimitriou JC, Raghavan P, Hatten KM. [Regionalization of head and neck oncology tumor boards: Perspectives of collaborating physicians.](#) *OTO Open.* 2023 Feb 28;7(1):e18.
7. Babier A, Mahmood R, Zhang B....**Soomro MH**, et al. [OpenKBP-Opt: an international and reproducible evaluation of 76 knowledge-based planning pipelines.](#) *Phys Med Biol.* 2022 Sep 12;67(18).
8. Baig MMFA, Fatima A, Gao X, Farid A, **Ajmal Khan M**, Zia AW, Wu H. [Disrupting biofilm and eradicating bacteria by Ag-Fe₃O₄@MoS₂ MNPs nanocomposite carrying enzyme and antibiotics.](#) *J Control Release.* 2022 Dec;352:98-120. Epub 2022 Oct 19.
9. Baig MMFA, Ma J, Gao X, **Khan MA**, Ali A, Farid A, Zia AW, Noreen S, Wu H. [Exploring the robustness of DNA nanotubes framework for anticancer theranostics toward the 2D/3D clusters of hypopharyngeal respiratory tumor cells.](#) *Int J Biol Macromol.* 2023 May 1;236:123988. Epub 2023 Mar 11.
10. **Becker SJ**, Lipson EJ, Jozsef G, **Molitoris JK**, Silverman JS, Presser J, Kondziolka D. [How many brain metastases can be treated with stereotactic radiosurgery before the radiation dose delivered to normal brain tissue rivals that associated with standard whole brain radiotherapy?](#) *J Appl Clin Med Phys.* 2023 Jan 11:e13856. Online ahead of print.
11. **Benda R**. Chapter 10: Prepectoral breast reconstruction radiation therapy. In: Vidya R, Becker H., eds. [Prepectoral breast reconstruction: current trends and techniques.](#) 1st ed. *Springer*; 2023 Jan.

12. **Bentzen SM**, Vogelius IR. [Using and understanding survival statistics - or how we learned to stop worrying and love the Kaplan-Meier estimate.](#) *Int J Radiat Oncol Biol Phys.* 2023 Mar 15;115(4):839–846.
13. **Biswal NC, Rodrigues DB, Yao W, Molitoris JK, Witek ME, Chen S.** [Evaluation of intrafraction couch shifts for proton treatment delivery in head-and-neck cancer patients: Toward optimal imaging frequency.](#) *J Appl Clin Med Phys.* 2022 Oct 14:e13795. Online ahead of print.
14. Burr A, Harari P, Wieland A, Kimple R, Hartig G, **Witek M.** [Patterns of failure for hypopharynx cancer patients treated with limited high-dose radiotherapy treatment volumes.](#) *Radiat Oncol J.* 2022 Dec 2. Online ahead of print.
15. **Cao Y, Kunaprayoon D, Xu J, Ren L.** [AI-assisted clinical decision making \(CDM\) for dose prescription in radiosurgery of brain metastases using three-path three-dimensional CNN.](#) *Clin Transl Radiat Oncol.* 2022 Dec 20;39:100565.
16. Chan A, **Bentzen S**, Rout A, Miller K. [Predicting if lung cancer will relapse-The role of neutrophil/lymphocyte ratio.](#) *Hematol Oncol Stem Cell Ther.* 2023 Jan 17;16(2):158–161.
17. Chen G, Li Z, Wang J, Wang J, Du S, **Zhou J**, Shi J, Zhou Y. [An improved 3D KiU-net for segmentation of liver tumor.](#) *Comput Biol Med.* 2023 May 4;160:107006. Online ahead of print.
18. Coburn KM, Roth B, Varney KM, **Carrier F**, Weber DJ. [¹H, ¹³C, and ¹⁵N assignments of the mRNA binding protein hnRNP A18.](#) *Biomol NMR Assign.* 2022 Dec 21. Online ahead of print.
19. Deek MP, Van der Eecken K, Sutura P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, **Mishra M, Rana Z, Molitoris J**, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, **Bentzen SM**, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, **Tran PT.** [Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials.](#) *J Clin Oncol.* 2022 Aug 24;JCO2200644.
20. Eckstein J, Choi JI, Lozano A, Ohri N, Press R, Hasan S, Kabarriti R, Chang J, Urbanic J, Durci M, Mohammed N, Stevens C, Tsai H, Apisarnthanarax S, **Regine W**, Vargas C, Nichols R Jr, Herman J, Simone CB 2nd, Chhabra A. [Proton therapy for unresectable and medically inoperable locally advanced pancreatic cancer: Results from a multi-institutional prospective registry.](#) *Adv Radiat Oncol.* 2023 Apr 23;8(5):101250. eCollection 2023 Sep-Oct.
21. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, **Tran PT**, Spratt DE, Pugh S, Feng FY, Mohamad O. [Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.](#) *NPJ Digit Med.* 2023 Feb 22;6(1):27.
22. Evans SB, Blitzblau RC, Chapman CH, Chollet-Lipscomb C, Deville C, Ford E, Gibbs IC, Howell K, Peters GW, Ponce SB, Seldon C, Spector-Bagdady K, Tarbell N, Terezakis S, **Vyfhuis MAL**, Wright J, Zietman A, Jagsi R. [Restricted access to abortion, the Dobbs ruling, and radiation oncology: Standing united against reproductive injustice.](#) *Int J Radiat Oncol Biol Phys.* 2022 Aug 10;S0360-3016(22)02598-6.
23. **Francis MR, Mohindra P**, Mooney-Doyle K. [Exploring dyad-based communication during cancer: A pilot study.](#) *Cancer Nurs.* 2022 Dec 1. Online ahead of print.
24. Geng H, Liao Z, Nguyen QN, Berman AT, Robinson C, Wu A, Nichols RC Jr, Willers H, Mohammed N, **Mohindra P**, Xiao Y. [Implementation of machine learning models to ensure radiotherapy quality for multicenter clinical trials: Report from a phase III lung cancer study.](#) *Cancers (Basel).* 2023 Feb 5;15(4):1014.
25. Ghita I, Piperi E, Atamas SP, **Bentzen SM**, Ord RA, Dyalram D, Lubek JE, Younis RH. [Cytokine profiling in plasma distinguishes the histological inflammatory subtype of head and neck squamous](#)

- cell carcinoma and a novel regulatory role of osteopontin. *Front Oral Health*. 2022 Sep 12;3:993638.
26. **Gibbs A**, Gupta P, Mali B, **Poirier Y**, Gopalakrishnan M, **Newman D**, **Zodda A**, Down JD, Serebrenik AA, Kaytor MD, Jackson IL. [A C57L/J mouse model of the delayed effects of acute radiation exposure in the context of evolving multi-organ dysfunction and failure after total-body irradiation with 2.5% bone marrow sparing](#). *Radiat Res*. 2023 Mar 2. Online ahead of print.
 27. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, **Tran PT**, Berlin A. [Stereotactic body radiation therapy for oligometastasis: GUst do it?](#) *Int J Radiat Oncol Biol Phys*. 2022 Nov 15;114(4):561-570.
 28. Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, **Tran PT**, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. [A phase 1 trial of durvalumab in combination with bacillus calmette-guerin \(BCG\) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study](#). *Eur Urol*. 2023 Jan 28:S0302-2838(23)00025-8. Online ahead of print.
 29. Hallemeier CL, Moughan J, Haddock MG, Herskovic AM, Minsky BD, **Suntharalingam M**, Zeitzer KL, Garg MK, Greenwald BD, Komaki RU, Puckett LL, Kim H, Lloyd S, Bush DA, Kim HE, Lad TE, Meyer JE, Okawara GS, Raben A, Schefter TE, Barker JL Jr, Falkson CI, Videtic GMM, Jacob R, Winter KA, Crane CH. [Association of radiotherapy duration with clinical outcomes in patients with esophageal cancer treated in NRG Oncology trials: A secondary analysis of NRG Oncology randomized clinical trials](#). *JAMA Netw Open*. 2023 Apr 3;6(4):e238504.
 30. Hooshangnejad H, **Han D**, Feng Z, Dong L, Sun E, Du K, Ding K. [Systematic study of the iodinated rectal hydrogel spacer material discrepancy on accuracy of proton dosimetry](#). *J Appl Clin Med Phys*. 2022 Sep 15:e13774. Online ahead of print.
 31. Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, **Tran PT**. [Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers](#). *Eur Urol Oncol*. 2022 Oct 22:S2588-9311(22)00171-7. Online ahead of print.
 32. Iqbal GMD, Zhang H, **D'Souza W**, Ha L, Rosenberger JM. [Four-dimensional computed tomography-based ventilation imaging in intensity-modulated radiation therapy treatment planning for pulmonary functional avoidance](#). *J Appl Clin Med Phys*. 2023 Feb 2:e13920. Online ahead of print.
 33. **Jiang K**, **MacFarlane M**, **Mossahebi S**, **Zakhary MJ**. [Evaluation of treatment planning system accuracy in estimating the stopping-power ratio of immobilization devices for proton therapy](#). *J Appl Clin Med Phys*. 2023 Jan 2:e13831. Online ahead of print.
 34. Jiang Z, Polf JC, Barajas CA, Gobbert MK, **Ren L**. [A feasibility study of enhanced prompt gamma imaging for range verification in proton therapy using deep learning](#). *Phys Med Biol*. 2023 Feb 27. Online ahead of print.
 35. Jiang Z, Sun L, **Yao W**, Wu QJ, Xiang L, **Ren L**. [3D in vivo dose verification in prostate proton therapy with deep learning-based proton-acoustic imaging](#). *Phys Med Biol*. 2022 Oct 7. Online ahead of print.
 36. **Kalavagunta C**, **Xu H**, **Zhang B**, **Mossahebi S**, **MacFarlane M**, **Jiang K**, **Lee SW**, **Chen S**, **Sawant A**, **Gopal A**, **Yi B**. [Is a weekly qualitative picket fence test sufficient? A proposed alternate EPID-based weekly MLC QA program](#). *J Appl Clin Med Phys*. 2022 Aug;23(8):e13699.
 37. **Kerans SJ**, **Samanta S**, **Vyfhuis MAL**, **Guerrero M**, **Bang CK**, **Mishra MV**, **Rana Z**, **Amin PP**, **Kwok Y**, **Naslund MJ**, **Molitoris JK**. [Racial analysis of clinical & biochemical outcomes in](#)

- prostate cancer patients treated with low-dose-rate brachytherapy. *Int J Radiat Oncol Biol Phys*. 2022 Nov 3;S0360-3016(22)03474-5. Online ahead of print.
38. **Khan MA**, Amin A, Farid A, Ullah A, Waris A, Shinwari K, Hussain Y, Alsharif KF, Alzahrani KJ, Khan H. [Recent advances in genomics-based approaches for the development of intracellular bacterial pathogen vaccines](#). *Pharmaceutics*. 2022 Dec 31;15(1):152.
 39. Kline K, Chen W, Kallen ME, Koka R, Omili D, Fan X, Iragua T, Gebru E, Dishanthan N, Baker JM, Dietze KA, Yared JA, **Hankey K**, Dahiya S, Niederhaus SV, Dunleavy K, Hardy NM, Leutkens T, Rapoport A, Atanackovic D. [Chimeric antigen receptor \(CAR\) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder \(PTLD\)](#). *Hum Vaccin Immunother*. 2023 Jun 6;2216116. Online ahead of print.
 40. **Kogan AA**, Topper MJ, Dellomo AJ, Stojanovic L, **McLaughlin LJ**, Creed TM, Eberly CL, Kingsbury TJ, Baer MR, Kessler MD, Baylin SB, **Rassool FV**. [Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia](#). *Proc Natl Acad Sci U S A*. 2022 Jul 5;119(27):e2123227119.
 41. Kowalchuk RO, Spears GM, Morris LK, Owen D, Yoon HH, Jethwa K, Chuong MD, **Ferris MJ**, Haddock MG, Hallemeier CL, Wigle D, Lin SH, Merrell KW. [Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer](#). *Front Oncol*. 2023 Feb 9;13:1081024. eCollection 2023.
 42. **Krc RF**, Singh SA, Fang W, Weir JS. [Photobiomodulation during chemoradiation for head and neck cancer: Effect on mucositis, weight loss, and feeding tube dependence](#). *Adv Radiat Oncol*. 2023 Mar 10;8(4):101216. eCollection 2023 Jul-Aug.
 43. Lee EE, Singh T, Hu C, Han M, Deville CJ, Halthore A, Greco S, **Tran P**, DeWeese T, Song DY. [The impact of salvage radiotherapy initiation at PSA \$\leq\$ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy](#). *Prostate*. 2022 Oct 31. Online ahead of print.
 44. Matsui JK, Perlow HK, Baiyee C, Ritter AR, **Mishra MV**, Bovi JA, Gondi V, Brown PD, Loughan AR, Leeper HE, Dawson E, Palmer JD. [Quality of life and cognitive function evaluations and interventions for patients with brain metastases in the radiation oncology clinic](#). *Cancers (Basel)*. 2022 Sep 1;14(17):4301.
 45. McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M 3rd, Dess R, **Mishra MV**, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. [Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126](#). *Cancer*. 2022 Dec 29. Online ahead of print.
 46. Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, **Mishra MV**, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. [Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: Secondary analysis of a phase 3 randomised trial](#). *Eur Urol*. 2023 Jan 27;S0302-2838(23)00056-8. Epub ahead of print.
 47. Mena E, Shih J, Chung JY, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-Moreno R, Saboury B, Jakhete N, **Molitoris JK**, Unger KR, Choyke PL, Escorcía FE. [Functional Imaging of Liver Cancer \(FLIC\): Study protocol of a phase 2 trial of \$^{18}\text{F}\$ -DCFPyL PET/CT imaging for patients with hepatocellular carcinoma](#). *PLoS One*. 2022 Nov 11;17(11):e0277407.
 48. Merfeld EC, Witek ME, Francis DM, Burr AR, Wallace CR, Kuczmaraska-Haas A, **Lamichhane N**, Kimple RJ, Glazer TA, Wieland AM, McCulloch TM, Hartig GK, Harari PM. [Interstitial brachytherapy for lip cancer: Technical aspects to individualize treatment approach and optimize outcomes](#). *Pract Radiat Oncol*. 2023 Jan 25;S1879-8500(23)00006-1. Online ahead of print.
 49. Miles D, Sforza D, Wong JW, Gabrielson K, Aziz K, Mahesh M, Coulter JB, Siddiqui I, **Tran PT**, Viswanathan AN, Rezaee M. [FLASH effects induced by orthovoltage X-rays: FLASH with x-ray](#)

- tubes - an *in vivo* study. *Int J Radiat Oncol Biol Phys*. 2023 Jun 24:S0360-3016(23)00590-4. Online ahead of print.
50. **Molitoris JK**. Start combining, stop comparing. *Int J Radiat Oncol Biol Phys*. 2023 Feb 1;115(2):279.
 51. Muir B, Culbertson W, Davis S, Kim GY, **Lee SW**, Lowenstein J, Renaud J, Sarfehnia A, Siebers J, Tantot L, Tolani N. **AAPM WGTG51 Report 374: Guidance for TG-51 reference dosimetry**. *Med Phys*. 2022 Aug 24. Online ahead of print.
 52. Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M 3rd, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, **Tran P**, Feng FY. **Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials**. *Int J Radiat Oncol Biol Phys*. 2022 Dec 31:S0360-3016(22)03688-4. Online ahead of print.
 53. Olson JD, Tooze JA, Bourland DJ, Cline JM, **Faria EB**, Cohen EP. **Measurement of renal cortical fibrosis by CT scan**. *Res Diagn Interv Imaging*. 2023 Mar;5:100024.
 54. Pan L, Chen X, **Rassool FV**, Li C, Lin J. **LLL12B, a novel small-molecule STAT3 inhibitor, induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells**. *J Biomedicine*. 2022 Aug 18;10(8):2003.
 55. Parsons D, Joo M, Iqbal Z, Godley A, Kim N, Spangler A, Albuquerque K, **Sawant A**, Zhao B, Gu X, Rahimi A. **Stability and reproducibility comparisons between deep inspiration breath-hold techniques for left-sided breast cancer patients: A prospective study**. *J Appl Clin Med Phys*. 2023 Jan 23:e13906. Online ahead of print.
 56. Patel CG, Peterson J, Aznar M, Tseng YD, Lester S, Pafundi D, Flampouri S, **Mohindra P**, Parikh RR, Mailhot Vega R, Konig L, Plastaras JP, Bates JE, Loap P, Kirova YM, Orlandi E, Lütgendorf-Caucig C, Ntentas G, Hoppe B. **Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations**. *Radiother Oncol*. 2022 Oct 14;177:21-32. Online ahead of print.
 57. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, **Tran PT**, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. **External beam radiotherapy with or without brachytherapy boost in men with very high-risk prostate cancer: A large multicenter international consortium analysis**. *Int J Radiat Oncol Biol Phys*. 2022 Sep 27:S0360-3016(22)03399-5.
 58. Pati S, Baid U, Edwards B, ... **Alexander GS**, ... Menze B, Barnholtz-Sloan JS, Martin J, Bakas S. **Federated learning enables big data for rare cancer boundary detection**. *Nat Commun*. 2022 Dec 5;13(1):7346.
 59. **Pollock AE**, **Arons D**, **Alexander GS**, **Alicia D**, **Birkman KM**, **Molitoris JK**, Mehra R, Cullen KJ, Hatten KM, Taylor RJ, Wolf JS, **Regine WF**, Witek ME. **Gross tumor volume margin and local control in p16-positive oropharynx cancer patients treated with intensity modulated proton therapy**. *Head Neck*. 2023 Feb 25. Online ahead of print.
 60. **Pollock AE**, Risher H, Berger M, Roque DM, Rao G, **Nichols EM**, **Mohindra P**. **Clinical outcomes of intensity modulated proton therapy reirradiation for gynecologic malignancies**. *Adv Radiat Oncol*. 2023 Feb 25;8(4):101191. eCollection 2023 Jul-Aug.
 61. Prabhu RS, Akinyelu T, Vaslow ZK, Matsui JK, Haghghi N, Dan T, **Mishra MV**, Murphy ES, Boyles S, Perlow HK, Palmer JD, Udovicich C, Patel TR, Wardak Z, Woodworth GF, Ksendzovsky A, Yang K, Chao ST, Asher AL, Burri SH. **Risk factors for progression and toxic effects after preoperative stereotactic radiosurgery for patients with resected brain metastases**. *JAMA Oncol*. 2023 Jun 8. Online ahead of print.

62. Puckett LL, Kodali D, Solanki A, Park JH, Katsoulakis E, Kudner R, Kapoor R, Kujundzic K, Chapman CH, Hagan M, Kelly M, Palta J, Bazan JG, Dragun A, Fisher C, Haffty B, **Nichols E**, Shah C, Salehpour M, Dawes S, Wilson E, Buchholz TA. [Consensus quality measures and dose constraints for breast cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology \(ASTRO\) Expert Panel.](#) *Pract Radiat Oncol.* 2022 Sep 14:S1879-8500(22)00271-5. Online ahead of print.
63. Rehman U, Faiz SM, Khalid AK, Khan MB, Hazrat A, Yahya M, **Ajmal Khan M**. [A new species of *Clitopilus Shanglayensis* \(Entolomatacesae, Agaricales\) reported from Khyber Pakhtunkhwa, Pakistan.](#) *Pakistan J Weed Sci Res.* 2022;28(2):160-168.
64. Rogers CL, Pugh SL, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Barani IJ, Braunstein S, Bovi JA, de Groot JF, Whitton AC, Lindhorst SM, Deb N, Shrieve DC, **Shu HK**, Bloom B, Machtay M, **Mishra MV**, Robinson CG, Won M, Mehta MP. [Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.](#) *Neuro Oncol.* 2023 Jan 5;25(1):137-145.
65. Roy S, **Dukic T**, **Bhandary B**, Tu KJ, **Molitoris J**, Ko YH, **Shukla HD**. [3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model.](#) *Am J Cancer Res.* 2022 Nov 15;12(11):4977-4987.
66. **Savla B**, **Hamza MA**, Yacubovich D, Cobbs S, Petrovska L, Scilla KA, Burrows W, Mehra R, Miller RC, Rolfo C, **Bentzen SM**, Mohindra P, **Vyfhuis MAL**. [The effect of body mass index \(BMI\) and residence in food priority areas \(FPAs\) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer.](#) *Int J Radiat Oncol Biol Phys.* 2023 Jan 28:S0360-3016(23)00080-9. Online ahead of print.
67. Shah C, **Mohindra P**, Vapiwala N, Campbell S, Bates JE, Mattes MD, Sim A, Fontanilla HP, Fields E, Pinnix CC, Haffty B. [The American Society for Radiation Oncology Workforce Statement.](#) *Int J Radiat Oncol Biol Phys.* 2022 Aug 17:S0360-3016(22)03135-2.
68. Sheng JY, Snyder CF, Smith KC, DeSanto J, Mayonado N, Rall S, White S, Blackford AL, Johnston FM, Joyner RL Jr, Mischtschuk J, Peairs KS, Thorner E, **Tran PT**, Wolff AC, Choi Y. [Evaluating potential overuse of surveillance care in cancer survivors.](#) *Cancer Med.* 2022 Nov 11. Online ahead of print.
69. Shinwari K, Rehman HM, Xiao N, Guojun L, **Khan MA**, Bolkov MA, Tuzankina IA, Chereshnev VA. [Novel high-risk missense mutations identification in *FAT4* gene causing Hennekam syndrome and Van Maldergem syndrome 2 through molecular dynamics simulation.](#) *Inform Med Unlock.* 2023;37:101160.
70. **Shukla HD**, **Dukic T**, **Roy S**, **Bhandary B**, Gerry A, **Poirier Y**, **Lamichhane N**, **Molitoris J**, **Carrier F**, Banerjee A, **Regine WF**, **Polf JC**. [Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response.](#) *Front Oncol.* 2023 Jan 12;12:1072774.
71. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeydi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, **Tran PT**, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. [The 5-hydroxymethylcytosine landscape of prostate cancer.](#) *Cancer Res.* 2022 Nov 2;82(21):3888-3902.
72. Smith KC, White S, DeSanto J, Hannum S, Mayonado N, Ahuja N, Bowie J, Cowall D, Mischtschuk J, Peairs K, Thorner E, **Tran P**, Wolff A, Snyder C. [Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial.](#) *J Cancer Surviv.* 2022 Aug;16(4):791–800.
73. So EC, Zhou H, Greenwell A, Burch EE, Ji Y, Mériageon EY, Olsen HS, **Bentzen SM**, Block DS, Zhang X, Strome SE. [Complement component C1q is an immunological rheostat that regulates Fc:Fc\[Formula: see text\]R interactions.](#) *Immunogenetics.* 2023 Jun 15;75(4):369–383.

74. Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, **Tran PT**, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C. [Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus](#). *Int J Radiat Oncol Biol Phys*. 2022 Dec 31:S0360-3016(22)03691-4. Online ahead of print.
75. Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JM, Efstathiou JA, **Tran PT**, Sandler HM, Hall WA, Thompson DJ, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. [Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial](#). *Int J Radiat Oncol Biol Phys*. 2023 May 1:S0360-3016(23)00371-1. Online ahead of print.
76. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Consortium NPCA, Sandler HM, **Tran PT**, Rodgers JP, Esteva A, Yamashita R, Feng FY. [Artificial intelligence predictive model for hormone therapy use in prostate cancer](#). *Res Sq*. 2023 Apr 21:rs.3.rs-2790858. Preprint.
77. Sutura P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, **Mishra M, Rana Z, Molitoris J, Ferris M**, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, **Tran PT**. [WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer](#). *Int J Radiat Oncol Biol Phys*. 2023 Jan 25:S0360-3016(22)03628-8. Online ahead of print.
78. Sutura P, Skinner H, Witek M, **Mishra M, Kwok Y**, Davicioni E, Feng F, Song D, **Nichols E, Tran PT**, Bergom C. [Histology specific molecular biomarkers: Ushering in a new era of precision radiation oncology](#). *Semin Radiat Oncol*. 2023 Jul;33(3):232–242.
79. Sutura P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, **Rana Z, Ren L**, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, **Tran PT**. [Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer](#). *Eur Urol*. 2023 May 10:S0302-2838(23)02790-2. Online ahead of print.
80. Sutura PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, **Rana Z**, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, **Tran PT**, Deek MP, Ost P. [Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer](#). *Ann Oncol*. 2023 May 8:S0923-7534(23)00657-9. Online ahead of print.
81. **Tran PT**, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Wang H, Beer TM, Antonarakis ES. [Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial](#). *J Clin Oncol*. 2022 Nov 11:JCO2201662. Online ahead of print.
82. **Tran PT**, Sutura P, Phillips RM, Deek MP, Chmura S. [From idea to clinical practice: a brief history of oligometastatic disease](#). *Int J Radiat Oncol Biol Phys*. 2022 Nov 15;114(4):576-580.
83. Valenzi E, Bahudhanapati H, Tan J, Tabib T, Sullivan DI, Nouraie M, Sembrat J, Fan L, Chen K, Liu S, Rojas M, **Lafargue A**, Felsher DW, **Tran PT**, Kass DJ, Lafyatis R. [Single-nucleus](#)

- chromatin accessibility identifies a critical role for TWIST1 in IPF myofibroblast activity. *Eur Respir J*. 2023 May 4;2200474. Online ahead of print.
84. Wang S, Ryan Russell J, Drescher M, Park A, Legesse T, Kundra V, **Tran PT**, Phelan M, Naslund M, Minhaj Siddiqui M. [Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy](#). *Prostate*. 2022 Aug 3. Online ahead of print.
 85. Wang X, Raman N, Lemtiri-Chlieh G, Chang J, Jagtap S, Chowdhury DD, Ballew M, **Carrieri FA**, Nguyen T, Nugent K, Peck T, Levine MS, Chan A, Lam C, Malek R, Hoang T, Phillips R, Cheng Z, Taparra K, Connis N, Hann CL, Holland A, **Tran PT**, **Lafargue A**, Wang H. [Griseofulvin radiosensitizes non-small cell lung cancer cells and activates cGAS](#). *Mol Cancer Ther*. 2023 Feb 7:MCT-22-0191. Online ahead of print.
 86. Ward MC, Fasola CE, White RL Jr, **Bentzen SM**, Khan AJ, Vicini F, Shah C. In regard to Vaidya et al. *Int J Radiat Oncol Biol Phys*. 2023 Jan 1;115(1):255–256.
 87. Waxer JF, Wong K, **Modiri A**, Charpentier AM, Moiseenko V, Ronckers CM, Taddei PJ, Constone LS, Sprow G, Tamrazi B, MacDonald S, Olch AJ. [Risk of cerebrovascular events among childhood and adolescent patients receiving cranial radiation therapy: A pediatric normal tissue effects in the clinic normal tissue outcomes comprehensive review](#). *Int J Radiat Oncol Biol Phys*. 2022 Sep 1:S0360-3016(22)00643-5
 88. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, **Tran PT**, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. [A novel prostate cancer subtyping classifier based on luminal and basal phenotypes](#). *Cancer*. 2023 Apr 14. Online ahead of print.
 89. Witek ME, Morris CG, **Alexander GS**, Dontu P, **Koroulakis AI**, **Regine WF**, Mendenhall WM. [Multi-institutional study of clinical outcomes of patients with head and neck cancer presenting with cN3 disease](#). *Head Neck*. 2023 Feb 28. Online ahead of print.
 90. **Xu H**, **Cheston SB**, **Gopal A**, **Zhang B**, **Chen S**, Yu S, Hall A, **Dudley S**. [A study of skin marker alignment using different diamond-shaped light fields for prone breast external-beam radiation therapy](#). *J Appl Clin Med Phys*. 2022 Aug 27:e13772.
 91. Yang Y, Zhang L, **Ren L**, Zhou L, Wang X. [SuperMini-seg: An ultra lightweight network for COVID-19 lung infection segmentation from CT images](#). *Biomed Signal Process Control*. 2023 Aug;85:104896. Epub 2023 Mar 21.
 92. **Yao W**, **Zhang B**, Han D, **Polf J**, **Vedam S**, **Lasio G**, **Yi B**. [Use of CBCT plus plan robustness for www.nlmreducing QACT frequency in intensity-modulated proton therapy: Head-and-neck cases](#). *Med Phys*. 2022 Aug 6. Online ahead of print.
 93. **Yi B**, **Sawant A**, **Chen S**, **Lee SW**, **Zhang B**. [Readiness for radiation treatment continuity: Survey on contingency plans against cyberattacks](#). *Adv Radiat Oncol*. 2022 Sep 16;7(5):100990.
 94. Zhong H, **Ren L**, Lu Y, Liu Y. [On the correction of respiratory motion-induced image reconstruction errors in positron-emission tomography-guided radiation therapy](#). *Phys Imaging Radiat Oncol*. 2023 Mar 16;26:100430.